Xenetic Biosciences, Inc. announced that it has entered into a security purchase agreement for the issuance of 850,000 shares at a price of $0.5751 per common share for gross proceeds of $488,835 on October 12, 2022. The transaction will include participation from CLS Therapeutics, LLC. The company will issue securities pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.08 USD | +0.25% |
|
+1.75% | +18.26% |
May. 22 | Xenetic Biosciences, Inc. Announces Management Resignations | CI |
May. 22 | Xenetic Biosciences, Inc. Announces Chief Executive Officer Changes | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.26% | 6.27M | |
+20.12% | 127B | |
+25.25% | 117B | |
+25.56% | 27.77B | |
-19.51% | 20.44B | |
-14.36% | 16.62B | |
-15.63% | 15.92B | |
-46.67% | 14.94B | |
+11.89% | 14.74B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- XBIO Stock
- News Xenetic Biosciences, Inc.
- Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, LLC